Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This randomized, Phase III, multicenter, open‐label study designed to evaluate the efficacy of Atezolizumab in combination with carboplatin, paclitaxel, bevacizumab compared with treatment with pemetrexed, cisplatin in approximately 228 TKI(tyrosine kinase inhibitor) pre treated patients with Stage IV non squamous non small cell lung cancer with activating EGFR mutation or ALK translocation.
Epistemonikos ID: 9fb428d2b7025916d4c4755e227e0b5d641843f2
First added on: May 22, 2024